SOMATROPIN

Brand name:

• Saizen®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Severe late onset growth hormone deficiency (GHD)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (Category 3)

Comment:

--

Submission sponsor:

Merck Healthcare Pty Ltd

Other PBAC consideration:

--

Submission received for:

September 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 01/09/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Exception applied

Lodgement of required documentation:

11/09/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/09/2023

Status:

Finalised

Government processes:

Commenced on 19/09/2023

Medicine listed on the PBS:

01/11/2023 (see PBS schedule)

---